AstraZeneca Coronavirus Vaccine Candidate Shows Up to 90% Efficacy in Interim Analysis
For the third time this month, a high-profile coronavirus vaccine has been shown to be extremely effective in keeping the global health scourge at bay. AstraZeneca (NASDAQ: AZN) reported late Sunday that AZD1222, the vaccine it is developing with the University of Oxford, met its primary endpoint of protection from COVID-19, according to an independent data-safety monitoring board.
The findings come from an interim analysis of clinical trials for the vaccine candidate taking place in the U.K. and in Brazil. The analysis comprises a total of 131 COVID-19 cases.
The data from the studies indicate the average efficacy of AZD1222 was 70%. One of the two dosing regimens, in which the vaccine was administered as a half-dose with a full-dose booster following at least one month later, showed an efficacy rate of 90%. The other, in which two full doses were given within the same time parameters, showed a 62% rate.
Source Fool.com
